Reportedly, PD-L1 expression on tumor cells (TCs) in SCLC is quite low, with a range of 1.8% to 17%, whereas PD-L1 expression is more frequent on immune cells (ICs) compared to TCs, ranging from 25.8 to 40% [34–47]. This evidence concerns the gene CD274 and neoplasm.